Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry

Lanreotide depot (LD; commercial name Somatuline(®) Depot) is an injectable, extended-release formulation of the synthetic somatostatin analog (SSA) lanreotide. In recent clinical trials, LD was found to be suitable for self or partner administration, avoiding the need to travel to a medical facilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvatori, Roberto, Woodmansee, Whitney W., Molitch, Mark, Gordon, Murray B., Lomax, Kathleen G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895214/
https://www.ncbi.nlm.nih.gov/pubmed/23314980
http://dx.doi.org/10.1007/s11102-012-0460-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895214/
https://www.ncbi.nlm.nih.gov/pubmed/23314980
http://dx.doi.org/10.1007/s11102-012-0460-2

Ejemplares similares